Cipla launches daptomycin for injection, 500 mg/vial
The single-dose vials are for intravenous use only
Cipla Limited and its subsidiary Cipla USA, Inc, have announced the launch of daptomycin for injection, 500mg/vial, single-dose vial, AP-rated generic equivalent of cubicin for injection in the United States.
According to IQVIA (IMS Health), cubicin for injection (daptomycin for injection) had US sales of approximately $606 million for the 12-month period ending June 2019. The product is available for shipping immediately.